FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product

The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand for its Covid jab, its only commercially available product.

A positive recommendation from the CDC would allow Moderna's vaccine to compete against GSK and Pfizer, which launched their respective shots in the U.S. last fall. Pfizer's vaccine has so far lagged behind GSK's, but both shots have so far recorded hundreds of millions in sales. The biotech company currently has more than 40 products in development, several of which are in late-stage trials. They include its combination shot targeting Covid and the flu, which could win approval as early as 2025.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Moderna says FDA delayed RSV vaccine approval to end of MayThe FDA has not informed Moderna of any issues related to the vaccine’s safety, efficacy or quality that would prevent its approval, the biotech company…
Source: NBCLA - 🏆 319. / 59 Read more »

Moderna says FDA delayed RSV vaccine approval to end of MayThe FDA has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said.
Source: CNBC - 🏆 12. / 72 Read more »